Ameet Mallik has served as a director since June 2021 and served as the Company’s Chief Executive Officer from May 1, 2021 to January 31, 2022. M. Mallik served as Executive Vice President and Head, U.S. Oncology of Novartis from November 2017 through April 2021. In this role, Mr. Mallik was responsible for Novartis’s commercial and medical oncology operations in the United States. From November 2015 to November 2017, Mr. Mallik served as Global Head, Marketing, Value and Access, and from April 2014 to November 2015 as Head, Latin America and Canada, both for Novartis Oncology. Mr. Mallik began his career at Novartis as Head of Strategic Planning and has held a number of commercial leadership roles at Novartis and Sandoz. At Sandoz, Mr. Mallik was Head of Biopharmaceuticals & Oncology Injectables at
Sandoz. Mr. Mallik previously worked as an Associate Principal at McKinsey and Company. Mr. Mallik has been a member of the board of Atara Biotherapeutics, Inc. (Nasdaq: ATRA) since August 2021. He also has been a member of the University of Pennsylvania, Life Sciences & Management Program Advisory
Board since November 2021. Mr. Mallik holds an M.B.A. from The Wharton School at the University of Pennsylvania, and an M.S. in Biotechnology and B.S. in Chemical Engineering, both from Northwestern University.
Current role
Non Executive Director at Australian Medical Students' Association
Executive Director at Great Schools Partnership
Managing Director at Wealth Excel
Director at IMPERIAL MONEY PVT. LTD.
Co-Founder & Managing Director at Bullshake Sportswear
Access the worlds's biggest network of public org charts
Learn more